Aeterna Zentaris: Phase 3 Results for AEZS-130 in AGHD to be Presented at Upcoming ENDO Meeting
QUÃ‰BEC CITY, June 14, 2012 /PRNewswire/ – Aeterna Zentaris Inc. (NASDAQ:
AEZS) (TSX: AEZ) (the ”Company”) today announced that Jose M. Garcia,
MD, PhD, of the Baylor College of Medicine and the Michael E. DeBakey
VA Medical Center in Houston, Texas, will be making an oral
presentation on Phase 3 results for AEZS-130 as an oral diagnostic test
for Adult Growth Hormone Deficiency (AGHD), at the 94(th )ENDO Annual Meeting and Expo which will be held June 23-26, 2012, in
Abstract #584: "AEZS-130 (Macimorelin) - Stimulated GH Test: Validation of a Novel Test for the Diagnosis of Adult Growth Hormone Deficiency (AGHD)", J. M. Garcia, R. Swerdloff, C. Wang, M. Kyle, M. Kipnes, B. Biller, D. Cook, K. Yuen, V. Bonert, A. Dobs, M. Molitch, G. Merriam. Date and time: Monday, June 25, 2012, at 11:15 am (Central) Session: CLINICAL - What's New in Diagnosis & Treatment of GH Dysfunction? Venue: Theater A, George R. Brown Convention Center, Houston, Texas
AEZS-130, a ghrelin agonist, is a novel orally-active small molecule
that stimulates the secretion of growth hormone. The Company has
completed a Phase 3 trial for use as an oral diagnostic test for AGHD.
AEZS-130 has been granted orphan drug designation by the FDA for use in
this indication. Aeterna Zentaris owns the worldwide rights to
About Aeterna Zentaris
Aeterna Zentaris is an oncology and endocrinology drug development
company currently investigating treatments for various unmet medical
needs. The Company’s pipeline encompasses compounds at all stages of
development, from drug discovery through to marketed products. For more
information please visit www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.